Literature DB >> 16135906

HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania.

Miguel A Arroyo1, Michael Hoelscher, Warren Sateren, Eleuter Samky, Leonard Maboko, Oliver Hoffmann, Gustavo Kijak, Merlin Robb, Deborah L Birx, Francine E McCutchan.   

Abstract

OBJECTIVE: To characterize HIV-1 strains in a potential vaccine trial cohort (CODE) in the Mbeya region of southwest Tanzania.
DESIGN: Study volunteers (n = 3096) were recruited from urban areas in Mbeya Town, using two different recruitment strategies, and in a nearby rural village.
METHODS: Cryopreserved plasma from 507 HIV-1 prevalent cases was the source of viral RNA for HIV-1 genotyping by the Multi-region Hybridization Assay, the MHA(acd), and selected strains were confirmed by complete genome sequencing.
RESULTS: The overall HIV-1 prevalence was 16.6% [95% confidence interval (CI), 15.3-17.9] within the cohort. HIV-1 prevalence was higher among women, and in urban areas. Recruitment through advertisement targeted a high-risk urban male population for HIV-1 infection [adjusted odds ratio (adj. OR), 1.68; 95% CI, 1.13-2.51] when compared with men recruited door-to-door. The complexity of the HIV-1 epidemic was also higher in urban areas evidenced by the high-risk of HIV-1 infection with a recombinant strain (adj. OR, 2.69; 95% CI, 1.08-6.69) and HIV-1 dual infection (adj. OR, 5.16; 95% CI, 1.07-24.9), mainly driven by urban men recruited through advertisement.
CONCLUSIONS: Overall the urban epidemic was more genetically complex, with higher prevalence and more recombinants and dual infections. Vaccine trials in Mbeya region can assess a complex HIV-1 population dynamic and determine vaccine efficacy in relationship to the genetic diversity of HIV-1 strains that challenge vaccines.

Entities:  

Mesh:

Year:  2005        PMID: 16135906     DOI: 10.1097/01.aids.0000183515.14642.76

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

1.  HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children.

Authors:  Michael J Boivin; Theodore D Ruel; Hannah E Boal; Paul Bangirana; Huyen Cao; Leigh A Eller; Edwin Charlebois; Diane V Havlir; Moses R Kamya; Jane Achan; Carolyne Akello; Joseph K Wong
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

2.  Natural killer cell-mediated innate sieve effect on HIV-1: the impact of KIR/HLA polymorphism on HIV-1 subtype-specific acquisition in east Africa.

Authors:  Rebecca N Koehler; Galit Alter; Sodsai Tovanabutra; Elmar Saathoff; Miguel A Arroyo; Anne M Walsh; Eric E Sanders-Buell; Leonard Maboko; Michael Hoelscher; Merlin L Robb; Nelson L Michael; Francine E McCutchan; Jerome H Kim; Gustavo H Kijak
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

3.  Prevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in rural Tanzania.

Authors:  Pax Masimba; Elimsaada Kituma; Thomas Klimkait; Edit Horvath; Marcel Stoeckle; Christoph Hatz; Erick Mossdorf; Emmanuel Mwaigomole; Salim Khamis; Boniphace Jullu; Salim Abdulla; Marcel Tanner; Ingrid Felger
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09       Impact factor: 2.205

4.  Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.

Authors:  Gustavo H Kijak; Sodsai Tovanabutra; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirapa Eamsila; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Chawetsan Namwat; Nakorn Premsri; Michael Benenson; Patricia Morgan; Meera Bose; Eric Sanders-Buell; Robert Paris; Merlin L Robb; Deborah L Birx; Mark S De Souza; Francine E McCutchan; Nelson L Michael; Jerome H Kim
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

5.  In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection.

Authors:  F E McCutchan; M Hoelscher; S Tovanabutra; S Piyasirisilp; E Sanders-Buell; G Ramos; L Jagodzinski; V Polonis; L Maboko; D Mmbando; O Hoffmann; G Riedner; F von Sonnenburg; M Robb; D L Birx
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Spatial and socio-behavioral patterns of HIV prevalence in the Democratic Republic of Congo.

Authors:  Jane P Messina; Michael Emch; Jeremie Muwonga; Kashamuka Mwandagalirwa; Samuel B Edidi; Nicaise Mama; Augustin Okenge; Steven R Meshnick
Journal:  Soc Sci Med       Date:  2010-08-05       Impact factor: 4.634

7.  Novel multiregion hybridization assay for the identification of the most prevalent genetic forms of the human immunodeficiency virus type 1 circulating in Portugal.

Authors:  Ferdinando B Freitas; Aida Esteves; João Piedade; Ricardo Parreira
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-25       Impact factor: 2.205

8.  Risk factors for HIV-1 infection in a longitudinal, prospective cohort of adults from the Mbeya Region, Tanzania.

Authors:  Steffen Geis; Leonard Maboko; Elmar Saathoff; Oliver Hoffmann; Christof Geldmacher; Donan Mmbando; Eleuter Samky; Nelson L Michael; Deborah L Birx; Merlin L Robb; Michael Hoelscher
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

9.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

10.  High-throughput high-resolution class I HLA genotyping in East Africa.

Authors:  Rebecca N Koehler; Anne M Walsh; Eric E Sanders-Buell; Leigh Anne Eller; Michael Eller; Jeffrey R Currier; Christian T Bautista; Fred Wabwire-Mangen; Michael Hoelscher; Leonard Maboko; Jerome Kim; Nelson L Michael; Merlin L Robb; Francine E McCutchan; Gustavo H Kijak
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.